Drug manufacturer AbbVie Inc. (ABBV) announced a collaboration with Tentarix Biotherapeutics on Thursday to use the latter's Tentacles platform for developing conditionally active, multi-specific biologic candidates in oncology and immunology.
The company said that it plans to expand its oncology and immunology portfolio with the partnership.
Under the partnership, Tentarix will receive an upfront payment of $64 million from AbbVie, which will in return receive an option to fully acquire the programs after candidate nomination for an additional undisclosed amount.
Currently, AbbVie's stock is trading at $174.56, down 0.33 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.